Key result
Higher baseline serum ANGPTL8/betatrophin levels were associated with a decreased risk of developing metabolic syndrome over 3.5 years in both males and females.
Why the study?
Do baseline serum ANGPTL8/betatrophin levels predict the development of metabolic syndrome in adults?
Cohort (n=153)
No
Do baseline serum ANGPTL8/betatrophin levels predict the development of metabolic syndrome in adults?
Serum ANGPTL8/betatrophin levels may serve as a useful biomarker for predicting the onset of metabolic syndrome in adults.
Answers are grounded in this paper and cite their sources.
Suggests ANGPTL8 as potential protective biomarker; hypothesis-generating and requires confirmation before clinical application.
ANGPTL8/betatrophin is a recently discovered hormone, which mainly synthesized and secreted by liver and adipose tissue, playing a critical role in pancreatic beta cell proliferation. Previous studies have suggested that serum ANGPTL8/betatrophin levels are associated with obesity and diabetes mellitus. Here, we evaluated the prospective association between ANGPTL8/betatrophin and the metabolic syndrome from a community-based cohort of 153 adults without metabolic syndrome. After 3.5-year follow-up, we observed an inverse correlation between the baseline ANGPTL8/betatrophin levels and the incidence of metabolic syndrome, even after multivariate adjustments. In receiver operating characteristic analysis, the area underneath the curve for ANGPTL8/betatrophin was 0.70 in males and 0.86 in females, and the optimal cut-off values were 23.9 ng/mL and 31.1 ng/mL, respectively. This article suggests that ANGPTL8/betatrophin might be useful in predicting newly-onset metabolic syndrome and its progression in clinical setting.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2016) conducted a cohort in Metabolic Syndrome (n=153). Higher serum ANGPTL8/betatrophin levels vs. Lowest quartile of ANGPTL8/betatrophin levels was evaluated on Incidence of metabolic syndrome (females) (OR 0.84, 95% CI 0.74-0.96, p=0.010). Higher baseline serum ANGPTL8/betatrophin levels were associated with a decreased risk of developing metabolic syndrome over 3.5 years in both males and females.
Synapse has enriched 10 related papers. Consider them for comparative context: